Brief: Cereno Scientific Reports Positive Results In Phase II Study Of CS1 In Rare Disease Pulmonary Arterial Hypertension
13/10/2023 21:58
Oct 13 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* CERENO SCIENTIFIC REPORTS POSITIVE RESULTS FROM THE DATA
QUALITY
CONTROL REVIEW INITIATIVE IN THE PHASE II STUDY OF CS1 IN RARE
DISEASE PULMONARY ARTERIAL HYPERTENSION (PAH)
* TOP-LINE RESULTS OF COMPLETED PHASE II STUDY ARE EXPECTED
IN Q1
2024
Source text for Eikon: ID:nWkr3CjsJt
Further company coverage: CRNOSb.ST
((Reuters.briefs@thomsonreuters.com;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln